SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Microcap & Penny StocksTLT.v


Previous 10 Next 10 
From: 3bar10/29/2019 7:50:21 AM
   of 1520
 
A reminder if you do your own investing you will do much better with a group of like minded who work in a way to complement each other . Having those clearly better informed then you in the group is a money saving necessity .

Do not try do do it alone .

Share RecommendKeepReplyMark as Last Read


From: Liberator11/1/2019 9:30:38 AM
   of 1520
 
I still have less than a full position in this...thank goodness.
Is Kipton's departure a positive or negative?

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth.

"We thank Kipton for his contributions to the Company over the last 8 months and we wish him well," said Theralase Technologies Chairman of the Board of Directors, Guy Anderson. "We are also excited with the prospects of the TLD-1433 Anti-Cancer Technology ("ACT") platform as it has the potential to be a viable treatment solution for patients who present with Carcinoma In-Situ ("CIS") Non-Muscle Invasive Bladder Cancer ("NMIBC") and who are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive."

The Company has commenced a Phase II NMIBC clinical study to enroll and treat patients who present with CIS and who are considered BCG-Unresponsive or are intolerant to BCG Therapy ("Study II"). The Company has three sites open for patient enrollment and treatment; specifically, University Health Network ("UHN"), McGill University Health Centre ("MUHC") and London Health Sciences Centre ("LHSC"). All sites are actively recruiting and screening new patients for enrollment in Study II. In addition, the Company has approximately six clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is specifically targeting strategic clinical sites throughout Canada and the US (subject to FDA Investigational New Drug ("IND") approval) that serve large populations or have the demographics to support patient enrollment and treatment. The Company anticipates that patient enrollment and treatment will escalate rapidly as it launches additional clinical study sites.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="About Theralase® Technologies Inc." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">About Theralase® Technologies Inc.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Liberator who wrote (1408)11/1/2019 12:02:36 PM
From: ogi
1 Recommendation   of 1520
 
Really hard to say what is going on. Given that TLT's 2000 system has been recalled by Health Canada for numerous deficiencies iit would be hard to blame that all on his first year. I assume he inherited many problems from RDW who, as part of his censure by the OSC, was disciplined for claiming full Government compliance in the laser division which was not true. So, one has to assume he was not comfortable that the opportunity he belived was ahead of him on hiring was not there in reality. If you have Linkedin keep an eye on him. Would love to do an exit survey with him:)

If you like the prospects of TLT but wish to minimize exposure there are the warrants TLT.wt, they have a 5 year term and give the right to purchase at .35. However I think the stock is the better deal at current prices

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


From: 3bar11/1/2019 12:11:02 PM
   of 1520
 
My take is sentiment has changed . Bollies are tight waiting for the news to break it out and up .

Share RecommendKeepReplyMark as Last Read


From: 3bar11/4/2019 12:18:57 PM
   of 1520
 
TLT.v as a risk/reward once in a life time investment ? Financial , Business execution = a tragedy for long time small retail .

Time A. This is a problem but the devices have taken time to develop . The criteria for a patient are detailed and is slowing things down .
Time B. We are only 6 to 8 months away from confirming a cure . See Photofrin + Bremachlorin both early generation PDC's .

Risk/reward this is the metric that may tell the story at this time . $5000 buys 20000 shares . If there is a glitch you may lose 1/2 your cash .
If 20 are clean which is probable from Phase 1 data $ 20 - 25 makes sense .

This guy always manages to pull a skunk out of his hat when your expecting a dove . But ???????????????

Share RecommendKeepReplyMark as Last Read


To: ogi who wrote (1409)11/8/2019 4:12:50 PM
From: Underexposed
2 Recommendations   of 1520
 
You may remember that I have been a long term player for a long time now. I have a quite significant holding and have not sold a share in about 5 years now {sigh}.

I look at the share price now and then but it is like watching paint dry, so I don't follow it daily. I don't anything about Kipton Lade so I don't understand if this is a good move or a sign of something bad.

Is Roger and his wife still active in the company...I would like to see the back of him.

My faith in the science is unshaken and the 3 major Canadian centers for Phase 2 are certainly good choices. The lack of movement on the share price is disappointing but this is not a quick flip, obviously. So I stay the course for now.

I thought I would do a complete TA analysis using my methods

First two Charts


The P&F Chart is not a slam dunk for an immediate rise. We see a really strong support between $0.20-$0.21 over 2 years but there is also a resistance band between $0.25 - $0.26 to contend with. These bands are so strong that a breach either way will be quite significant...But things are neutral bearish right now

The column SMAs are increasingly bearishly diverging... and shows no hint of reversing yet.

The "Trigger" Chart is like listening to a drum roll. The Share price is located in a decent spot.... the 20 day SMA is $0.216 and the current share price is $0.22 so we are at or over the 20 day SMA today.

I'll start at the bottom for indicators.... The Bollies are very tight as you can see in the main chart and the BBwidth has flatlined for almost 3 weeks now. This in itself is neither bullish or bearish.... it just means at some point in the future there will be a breakout.... either up or down it depends on the other 2 indicators for a prediction.

The MACD is fine though it is hardly a dynamic rise....but it is a rise nonetheless.

The Slow sto is the iffy indicator.... right now it is wandering between 0 -35... we want the Slow sto to start to rise over 50 heading for 80+

the Slow Sto and MACD lead a break up/down.

Right now I would say we are neutral bullish as the chart as a whole. We are just looking for a sudden rise in the Slow Sto , followed by continued rise in the MACD and then the "trigger" of the BBWidth sudden rise.

What we don't want to see is a negative reversal to the MACD and the dive of the Slow sto before the sudden rise of the BBwidth.

As the man said falling off the bridge...."so far...so good" :)



My sentiment chart offers a bit of hope

The Parabolic Sar is an eyelash away from reversing direction in the main chart. mildly bearish

The Force 30 is steadily trying for positive ground (mildly bearish)

The RSI(30) and the DL +/- are both neutral

The Ichimoku chart tells us a lot.

In the main chart you see that the share price has been under a red cloud since the beginning of the year and now we are reaching for the lower edge of the red cloud and that is a resistance line. I drew 3 circles in the main chart.... The first shows the approach to the bottom of the red cloud the second shows a long steady resistance and the third sows a weakness of that cloud.

I can see the share price scudding below that cloud below the red cloud til we reach that weakness and THAT is our chance to rise above said cloud.

The On Bal volume is neutral

The CCI is neutral bearish

The CMF currently is bearish

Conclusion


Unfortunately I don't see a positive breakout yet.... but then I don't see a sudden drop either. I see more of the same for the rest of the month until the first week of December.... at that point with the weakness of that red cloud we have a chance to rise...

Hope this helps

UE

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Underexposed who wrote (1412)11/8/2019 6:33:30 PM
From: ogi
   of 1520
 
I am incapable of fully appreciating your TA efforts. That does not mean I am not glad of them and that I still do get a benefit from them.

I think we are on the same page:

""But things are neutral bearish right now ""

Tlt is behaving exactly as it has in the past, so to your point, I am pretty sure Roger and CFO wife are still well in command.

The fact TLT's 2000 series lasers have been recalled by Health Canada and not a word said by the company just reeks. Pretty hard not to draw a connection between that fact and the departure of the new CEO of devices division.

I am fully convinced of the PDC technology, its promise and the strength of intellect behind it. The quality of the TLT medical personnel is superior, far different than "devices" . As am engineer, I expect RDW must be more deferential to the oncology division than to that of the devices. That said, it is hard to believe recruitment is so slow in Canada , while the U.S. sites have not been brought onboard yet.

Believe me , one of the most important DD criteria on any junior is the timing, price and terms of any private placements. Those terms indicate the quality of management. On that basis TLT is an exceptionally bad fund raiser and by extension an exceptionally bad management, new CEO has shown no positive impact to date.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: ogi who wrote (1413)11/8/2019 10:23:08 PM
From: Underexposed
   of 1520
 
The fact TLT's 2000 series lasers have been recalled by Health Canada and not a word said by the company just reeks. Pretty hard not to draw a connection between that fact and the departure of the new CEO of devices division.

Yeah, you are probably right...in reading the recall by health Canada it looks like a cluster-F for delivery. They have been making that TLC-2000 for years.... has this been a problem all along or did they jump the gun .... hard to say.

I don't think this affects the Phase II study at all as a different laser is being used.
That said, it is hard to believe recruitment is so slow in Canada , while the U.S. sites have not been brought onboard yet.
It is not unlike last time.... they have a very specific criteria that has to be met. I am encouraged that they at least have one candidate as of September and that Patient 6 and 5 are cancer free still.

I think they have an order to this trial... first Canadian sites.... 3 selected now.... then USA.... then Europe.

It is my guess they want to make any mistakes in this phase in Canada rather than shotgun it out immediately .... that is my guess anyway.

UE

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Underexposed who wrote (1414)11/9/2019 3:07:46 AM
From: 3bar
   of 1520
 
This is correct " I don't think this affects the Phase II study at all as a different laser is being used. "

2 separate systems the recall has no effect on the Phase 11 trial . This was verified by a phone call .

Share RecommendKeepReplyMark as Last Read


To: Underexposed who wrote (1414)11/11/2019 8:00:26 AM
From: ogi
   of 1520
 
Yes, I understand the recall is independent of the trial. But as you say a Cluster F and one that in my view must be closely related to the departure of the device division CEO. Ie is all well at head office? It is simply another incident that does not inspire confidence in a management that has already been sanctioned by the OSC. I think the medical division science is so complex, requires very specific skill sets and has such incredibly good scientists on board it is harder for bad management to interfere.

Tlt has stated Europe has been dropped in favour of just Canada and U.S..

The sooner the U.S. gets underway the sooner TLT has access to 10x the possible trial participants and the more TLT becomes attractive to U.S. investors.

I too continue to be encouraged by Phase 1 trial results and can only imagine phase 2 trial will have minor procedural improvements that will benefit the process and we shall see if the double dose also improves results.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)
Previous 10 Next 10